Johnson & Johnson’s DePuy Synthes PRSpin UnSpun: Bye-Bye to 400 Employees
July 2, 2014
TODAY Johnson & Johnson announced via spokesperson the company is undergoing a reorganization (Ethicon One?) that will eliminate approximately 400 jobs, or less than 2% of the global DePuy workforce of 23,000 employees.
Small number of jobs? Where have we seen that before? Oh yes!
And more importantly where is the actual press release? Why no actual spokeswoman name given? It’s not on the Johnson & Johnson DePuy Synthes website and the WSJ is the only source all other media outlets are citing. While that’s customary at a high profile press release for one (or three) outlets to get the information and provide it to the other outlets, why is it happening in this case? (think big trial verdict) Just another example of Johnson & Johnson Spinning their PR so well that even the media is missing they’re getting played?
Wow the WSJ sure is very pro JNJ (is this really fair and balanced reporting?)
Pinned? Does that mean they’re going steady?
And earlier this year: Ending Johnson & Johnson’s Ethicon’s Mentor’s PurTox development program will result in the elimination of a small number of jobs in the United States, the Johnson & Johnson said.
It would appear that Johnson & Johnson PR is BIG on using SMALL to diminish importance (like in KY when they pulled a small amount of product (in reality pulled millions of units) and again here with a small number of jobs, do we believe them?)
Johnson & Johnson Q1 profits are up 8% in part because of new drugs (guess PurTox isn’t one) and cutting production and administrative expenses (does that mean job loss for people?)
Johnson & Johnson’s DePuy Synthes seeks to resolve as many as 11,500 lawsuits in the U.S. and has considered paying more than $300,000 per case, according to the people. Such a settlement would exceed $3 billion if most plaintiffs accept the terms, an amount 50 percent larger than that proposed in previous discussions.
Johnson & Johnson’s DePuy Synthes unit recalled 93,000 implants in 2010, including 37,000 in the U.S., after more than 12 percent failed within five years. That rate is climbing, along with suits by patients blaming the chromium and cobalt devices for pain, metal debris and replacement surgeries.
And yet, Alex Gorsky CEO of Johnson & Johnson Worldwide at the helm of all these lawsuits and job loss still has a job. Ironic, huh?
Does the recent US Supreme Court Hobby Lobby decision which personifies a company now open the door for the newly released 400 Johnson & Johnson’s DePuy Synthes employees to Band-Aid together and sue the company for acting like a sociopath which caused their job loss?
And to keep looking behind the curtain the message boards (the anger and distrust from employees is almost always sparked by the truth) What companies miss (and hide behind) is that angry and disgruntled doesn’t mean what’s beings said isn’t TRUE:
Medtechy: Beginning of Ethicon One?
Cafepharma: Down Sizing Johnson & Johnson DePuy Synthes
Cafepharma: I used to work at DePuy Warsaw
That’ right Johnson & Johnson’s DePuy Synthes announced on June 26, 2014 they were cutting jobs in Warsaw
DePuy Synthes Cos. has eliminated an undisclosed number of jobs, affecting a portion of the company’s Warsaw workforce, an official confirmed Wednesday.
Lorie Gawreluk, vice president of Johnson & Johnson (DePuy Synthes) worldwide communications, said in an email that less than 2 percent of the company’s 23,000-person global workforce is affected by the job eliminations. Two percent would be 460 jobs.
“The impact of the job changes is global and across many sites and areas of our business,” Gawreluk said, declining to be more specific about the number of jobs lost in Warsaw. She also declined to provide an exact Warsaw employee headcount.
DePuy employed about 1,200 in the Kosciusko County city as of two years ago.
Ms. Gawreluk also didn’t explain how a company that saw 8% increase in profits in Q1 could possibly let employees go or to offer any company accountability to as to why:
Johnson & Johnson’s DePuy Synthes Oregon $4 million to resolve deceptive marketing claims over recalled metal-on-metal hip implants in its first accord with any governmental unit involving the devices. Bloomberg Karen Gullo
Read More Here JNJ & WSJ Advertising Case Study